| Application number | Title of the application | Filing Date | Status |
|---|
Array
(
[id] => 19338511
[patent_doc_number] => 12048682
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2024-07-30
[patent_title] => Combination of micheliolide derivatives or nanoparticles with ionizing radiation and checkpoint inhibitors for cancer therapy
[patent_app_type] => utility
[patent_app_number] => 17/855327
[patent_app_country] => US
[patent_app_date] => 2022-06-30
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 4
[patent_figures_cnt] => 4
[patent_no_of_words] => 12324
[patent_no_of_claims] => 16
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 48
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17855327
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/855327 | Combination of micheliolide derivatives or nanoparticles with ionizing radiation and checkpoint inhibitors for cancer therapy | Jun 29, 2022 | Issued |
Array
(
[id] => 19026368
[patent_doc_number] => 11925710
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2024-03-12
[patent_title] => Modified release compositions of a GAMMA-hydroxybutyric acid derivative
[patent_app_type] => utility
[patent_app_number] => 17/843097
[patent_app_country] => US
[patent_app_date] => 2022-06-17
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 26
[patent_figures_cnt] => 44
[patent_no_of_words] => 22815
[patent_no_of_claims] => 20
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 108
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17843097
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/843097 | Modified release compositions of a GAMMA-hydroxybutyric acid derivative | Jun 16, 2022 | Issued |
Array
(
[id] => 18107884
[patent_doc_number] => 20230000764
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-01-05
[patent_title] => PRESSURIZED NUTRITIONAL SUPPLEMENT DELIVERY
[patent_app_type] => utility
[patent_app_number] => 17/839128
[patent_app_country] => US
[patent_app_date] => 2022-06-13
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 1905
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -15
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17839128
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/839128 | PRESSURIZED NUTRITIONAL SUPPLEMENT DELIVERY | Jun 12, 2022 | Abandoned |
Array
(
[id] => 17894702
[patent_doc_number] => 20220304364
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-09-29
[patent_title] => ORAL PRODUCT AND METHOD OF MANUFACTURE
[patent_app_type] => utility
[patent_app_number] => 17/836661
[patent_app_country] => US
[patent_app_date] => 2022-06-09
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 17667
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 70
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17836661
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/836661 | ORAL PRODUCT AND METHOD OF MANUFACTURE | Jun 8, 2022 | Pending |
Array
(
[id] => 17881024
[patent_doc_number] => 20220296501
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-09-22
[patent_title] => ORAL COMPOSITION WITH POLYMERIC COMPONENT
[patent_app_type] => utility
[patent_app_number] => 17/834989
[patent_app_country] => US
[patent_app_date] => 2022-06-08
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 19795
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 141
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17834989
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/834989 | ORAL COMPOSITION WITH POLYMERIC COMPONENT | Jun 7, 2022 | Pending |
Array
(
[id] => 18167251
[patent_doc_number] => 20230033858
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-02-02
[patent_title] => DIRECT APPLICATION SYSTEM AND METHOD FOR THE DELIVERY OF BIOACTIVE COMPOSITIONS AND FORMULATIONS
[patent_app_type] => utility
[patent_app_number] => 17/832416
[patent_app_country] => US
[patent_app_date] => 2022-06-03
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 64108
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -1
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17832416
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/832416 | DIRECT APPLICATION SYSTEM AND METHOD FOR THE DELIVERY OF BIOACTIVE COMPOSITIONS AND FORMULATIONS | Jun 2, 2022 | Abandoned |
Array
(
[id] => 17881236
[patent_doc_number] => 20220296713
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-09-22
[patent_title] => BIOPHOTONIC COMPOSITIONS FOR TREATING SKIN AND SOFT TISSUE WOUNDS HAVING EITHER OR BOTH NON-RESISTANT AND RESISTANT INFECTIONS
[patent_app_type] => utility
[patent_app_number] => 17/745058
[patent_app_country] => US
[patent_app_date] => 2022-05-16
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 26086
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17745058
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/745058 | BIOPHOTONIC COMPOSITIONS FOR TREATING SKIN AND SOFT TISSUE WOUNDS HAVING EITHER OR BOTH NON-RESISTANT AND RESISTANT INFECTIONS | May 15, 2022 | Abandoned |
Array
(
[id] => 19279884
[patent_doc_number] => 20240216356
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-07-04
[patent_title] => TASTE MASKED COMPOSTIONS OF 2,4,6-TRIFLUORO-N-[6-(1-METHYL-PIPERIDINE-4-CARBONYL)-PYRIDIN-2-YL]-BENZAMIDE HEMISUCCINATE, AND ORALLY DISENTEGRATING TABLET COMPRISING THE SAME
[patent_app_type] => utility
[patent_app_number] => 18/557666
[patent_app_country] => US
[patent_app_date] => 2022-05-06
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 16297
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -22
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18557666
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/557666 | TASTE MASKED COMPOSTIONS OF 2,4,6-TRIFLUORO-N-[6-(1-METHYL-PIPERIDINE-4-CARBONYL)-PYRIDIN-2-YL]-BENZAMIDE HEMISUCCINATE, AND ORALLY DISENTEGRATING TABLET COMPRISING THE SAME | May 5, 2022 | Pending |
Array
(
[id] => 19496382
[patent_doc_number] => 20240335400
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-10-10
[patent_title] => GASTRIC RESIDENCE SYSTEMS COMPRISING METHADONE
[patent_app_type] => utility
[patent_app_number] => 18/289326
[patent_app_country] => US
[patent_app_date] => 2022-05-04
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 30151
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -25
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18289326
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/289326 | GASTRIC RESIDENCE SYSTEMS COMPRISING METHADONE | May 3, 2022 | Pending |
Array
(
[id] => 18183574
[patent_doc_number] => 20230044304
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-02-09
[patent_title] => Nitric oxide generation, dilution, analysis, and topical application compositions, systems, apparatus and methods
[patent_app_type] => utility
[patent_app_number] => 17/727651
[patent_app_country] => US
[patent_app_date] => 2022-04-22
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 35983
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17727651
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/727651 | Nitric oxide generation, dilution, analysis, and topical application compositions, systems, apparatus and methods | Apr 21, 2022 | Abandoned |
Array
(
[id] => 18108245
[patent_doc_number] => 20230001125
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-01-05
[patent_title] => NITRIC OXIDE GENERATION, DILUTION, AND TOPICAL APPLICATION COMPOSITIONS, SYSTEMS, APPARATUS AND METHODS
[patent_app_type] => utility
[patent_app_number] => 17/727630
[patent_app_country] => US
[patent_app_date] => 2022-04-22
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 6236
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17727630
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/727630 | NITRIC OXIDE GENERATION, DILUTION, AND TOPICAL APPLICATION COMPOSITIONS, SYSTEMS, APPARATUS AND METHODS | Apr 21, 2022 | Abandoned |
Array
(
[id] => 19246655
[patent_doc_number] => 20240197639
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-06-20
[patent_title] => CAPSULE FOR SPECIFIC DRUG DELIVERY AND PREPARATION METHOD THEREFOR
[patent_app_type] => utility
[patent_app_number] => 18/287244
[patent_app_country] => US
[patent_app_date] => 2022-04-20
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 8106
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18287244
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/287244 | CAPSULE FOR SPECIFIC DRUG DELIVERY AND PREPARATION METHOD THEREFOR | Apr 19, 2022 | Pending |
Array
(
[id] => 19338519
[patent_doc_number] => 12048690
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2024-07-30
[patent_title] => Unit oral dose compositions composed of naproxen sodium and famotidine for the treatment of acute pain and the reduction of the severity and/or risk of heartburn
[patent_app_type] => utility
[patent_app_number] => 17/658849
[patent_app_country] => US
[patent_app_date] => 2022-04-12
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 21928
[patent_no_of_claims] => 13
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 110
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17658849
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/658849 | Unit oral dose compositions composed of naproxen sodium and famotidine for the treatment of acute pain and the reduction of the severity and/or risk of heartburn | Apr 11, 2022 | Issued |
Array
(
[id] => 18018870
[patent_doc_number] => 20220370369
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-11-24
[patent_title] => FORMULATION OF INTRINSICALLY ACID-RESISTANT VEGETARIAN-BASED AND GELATIN-BASED SOFT GEL CAPSULES FOR PHARMACEUTICAL/ NUTRACEUTICAL PRODUCTS
[patent_app_type] => utility
[patent_app_number] => 17/711602
[patent_app_country] => US
[patent_app_date] => 2022-04-01
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 2607
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -14
[patent_words_short_claim] => 31
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17711602
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/711602 | FORMULATION OF INTRINSICALLY ACID-RESISTANT VEGETARIAN-BASED AND GELATIN-BASED SOFT GEL CAPSULES FOR PHARMACEUTICAL/ NUTRACEUTICAL PRODUCTS | Mar 31, 2022 | Abandoned |
Array
(
[id] => 17733178
[patent_doc_number] => 20220218637
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-07-14
[patent_title] => Volatile Organic Compound Formulations Having Antimicrobial Activity
[patent_app_type] => utility
[patent_app_number] => 17/705993
[patent_app_country] => US
[patent_app_date] => 2022-03-28
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 39082
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 30
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17705993
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/705993 | Volatile organic compound formulations having antimicrobial activity | Mar 27, 2022 | Issued |
Array
(
[id] => 18027733
[patent_doc_number] => 11510892
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2022-11-29
[patent_title] => Pharmacokinetics of combined release formulations of a g-hydroxybutyric acid derivative
[patent_app_type] => utility
[patent_app_number] => 17/698609
[patent_app_country] => US
[patent_app_date] => 2022-03-18
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 5
[patent_figures_cnt] => 7
[patent_no_of_words] => 31819
[patent_no_of_claims] => 15
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 50
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17698609
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/698609 | Pharmacokinetics of combined release formulations of a g-hydroxybutyric acid derivative | Mar 17, 2022 | Issued |
Array
(
[id] => 19155953
[patent_doc_number] => 20240148659
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-05-09
[patent_title] => LIQUID VISCOELASTIC SWALLOWING AID TO PROMOTE SAFE SWALLOWING OF SOLID ORAL DOSAGE FORMS (SODF)
[patent_app_type] => utility
[patent_app_number] => 18/549652
[patent_app_country] => US
[patent_app_date] => 2022-03-11
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 18439
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 108
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18549652
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/549652 | LIQUID VISCOELASTIC SWALLOWING AID TO PROMOTE SAFE SWALLOWING OF SOLID ORAL DOSAGE FORMS (SODF) | Mar 10, 2022 | Pending |
Array
(
[id] => 18777819
[patent_doc_number] => 11819494
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2023-11-21
[patent_title] => Treatment of idiopathic pulmonary fibrosis
[patent_app_type] => utility
[patent_app_number] => 17/680654
[patent_app_country] => US
[patent_app_date] => 2022-02-25
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 1
[patent_figures_cnt] => 1
[patent_no_of_words] => 14126
[patent_no_of_claims] => 19
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 54
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17680654
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/680654 | Treatment of idiopathic pulmonary fibrosis | Feb 24, 2022 | Issued |
Array
(
[id] => 17759903
[patent_doc_number] => 20220233515
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-07-28
[patent_title] => Pharmaceutical Composition
[patent_app_type] => utility
[patent_app_number] => 17/668811
[patent_app_country] => US
[patent_app_date] => 2022-02-10
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 15063
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 30
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17668811
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/668811 | Pharmaceutical Composition | Feb 9, 2022 | Abandoned |
Array
(
[id] => 19554719
[patent_doc_number] => 20240366511
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-11-07
[patent_title] => ORAL SOLID DOSE FORMULATIONS
[patent_app_type] => utility
[patent_app_number] => 18/262938
[patent_app_country] => US
[patent_app_date] => 2022-02-03
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 11645
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -20
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18262938
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/262938 | ORAL SOLID DOSE FORMULATIONS | Feb 2, 2022 | Pending |